- 장기 칩과 미소 생리 시스템 -

장기 칩과 미소 생리 시스템을 테마로 한 이 심포지엄에서는 유망 전임상 모델에 대해 분석 및 평가하는 세션이 예정되어 있으며, 보다 정확하고 신뢰성 높은 전임상 시험의 실현을 향한 향후 경로 등이 논의됩니다.

Recommended All Access Package:

11월 27일: 장기 칩과 미소 생리 시스템

11월 27일 Dinner Course: 쇼트코스 3:장기 칩 시스템의 기점, 최적화, 응용

11월 28-29일: 리드 화합물의 최적화와 약물 독성 예측

11월 29-30일: 3차원 세포 모델

11월 29일 Dinner Course: 쇼트코스 5:인간화 마우스 모델:기술 개요와 암 면역치료의 전임상 평가에 대한 응용

11월 27일(화)

7:00 Registration and Morning Coffee

단계 모델

8:20 Welcome Remarks

Joel Hornby, BSc, Conference Director, Cambridge Healthtech Institute

8:25 Chairperson’s Opening Remarks

James J. Hickman PhD, Professor, NanoScience Technology Center, University of Central Florida

8:30 Stem Cell Based MicroPhysiological Organ-on-a-Chip Systems as in vitro Models of Human Tissue with Physiological Structure and Function

Peter Loskill, PhD, Assistant Professor for Experimental Regenerative Medicine, Department of Women’s Health, Research Institute for Women’s Health, Faculty of Medicine, Eberhard Karls University Tübingen

Drug discovery and development to date has relied on animal models, which fail to resemble human physiology. The discovery of human induced pluripotent stem cells (hiPSC) has led to the emergence of a new paradigm of drug screening using patient- and disease-specific organ/tissue-models. One promising approach is the organ-on-a-chip system that integrates hiPSC-derived tissues in microphysiological environments and combines human genetic background, in vivo-like tissue structure, physiological functionality, and “vasculature-like” perfusion.

9:00 Lung Alveolar Models Based on Organs-on-Chip Technologies

Olivier Guenat, PhD, Head Organs-on-Chip Technologies, ARTORG Center, University of Bern

Organs-on-chips are able to recapitulate the in vivo cellular environment in unprecedented way and are widely expected to better predict drug’s response in humans than standard in vitro models. We will present several lung-on-chip models using primary cells from patients that closely recapitulate the cellular environment of the lung parenchyma. These functional models, which mimic the lung alveolar barrier as well as the lung microvasculature, are used to evaluate the effects of various compounds used for respiratory diseases, such as pulmonary fibrosis.

9:30 Vascularized Engineered CNS Organoids and MicroPhysiological Systems for the Evaluation of Developmental Neurotoxins and Modelling of CNS Disorders

William Daly, PhD, Human Models for Analysis of Pathway’s (H-MAP’s) Center Managing Director, University of Wisconsin

We have created a 3D vascularized stem cell derived organoid model (/microphysiological system) of the cerebral cortex in a microfluidics platform that has distinct neural, vascular and microglial components. The model captures the initial vascularization of the developing brain from the perineural vascular plexus in vitro and allows us to screen for compounds that may disrupt its formation resulting in later vulnerabilities or susceptibility in the blood brain barrier.

10:00 Coffee Break

다계 모델

10:30 Building Phenotypic Body-on-a-Chip Models for Preclinical Toxicological and Efficacy Evaluations Utilizing Stem Cell Derived Disease Models

James J. Hickman, PhD, Professor, NanoScience Technology Center, University of Central Florida

The utilization of human-on-a-chip systems that incorporate iPSCs allows for understanding different disease states by constructing them utilizing patient cells. We are constructing systems in serum-free medium with functional readouts that employs a pumpless platform. Our group has been constructing these systems with up to 6 organs and demonstrated up to 28 days evaluation of drugs and compounds, that have shown similar response to results seen from clinical data or literature reports.

11:00 Emulating the Gut-Liver Axis - Organ-on-Chip in Preclinical Research

Alexander S. Mosig, PhD, Assistant Professor, Center for Sepsis Control and Care, Jena University Hospital

To investigate the mechanism of infection-related organ dysfunction we developed a microfluidically perfused model of the human gut-liver axis. The in vitro model comprises tissue resident and circulating immune cells to emulate essential components of the human immune system. Biochip-integrated sensors allow continuous monitoring of environmental conditions and allow quantification of tissue integrity. A synthetic microbiome is being integrated to emulate microbiome-host interaction under physiological and pathophysiological conditions.

11:30 Sponsored Presentation (Opportunity Available)

12:00 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:30 Session Break

트랜스레이셔널 시스템과 응용 시스템

13:25 Chairperson’s Remarks

Peter Loskill, PhD, Assistant Professor for Experimental Regenerative Medicine, Department of Women’s Health, Research Institute for Women’s Health, Faculty of Medicine, Eberhard Karls University Tübingen

13:30 Modeling Rare Diseases with Organs-on-Chips

Danilo A. Tagle, MS, PhD, Associate Director for Special Initiatives, National Center for Advancing Translational Sciences, National Institutes of Health

Developing drugs for rare diseases can be challenging due to the small, heterogeneous patient populations, few disease experts and expert centers, variable and long time-frames for disease progression, a poor understanding of disease natural history, and a lack of prior clinical studies. Recent technological advances, particularly in the area of organs-on-chips and induced pluripotent stem cells (iPSCs) have created opportunities to create a paradigm shift in therapy development, especially in the area of rare disease research.

14:00 Reducing Attrition in Drug Discovery through the Use of Human Translational Cellular Models

Wendy Rowan, PhD, FRSB, Associate GSK Fellow, Scientific Leader Target Sciences, GlaxoSmithKline

Preclinical efficacy and toxicology data derived from in vitro and animal models often fails to translate to clinical trials, resulting in high rates of attrition and falling Research and Development productivity. The development of more predictive human in vitro systems represents one of the most urgent challenges facing the pharmaceutical industry. In a fast moving field, advances in bioengineering are showing the potential for transforming the outcome of drug discovery.

14:30 Maximizing the Impact of MicroPhysiological Systems with in vitro-in vivo Translation

Murat Cirit, PhD, Director, Biological Engineering, MIT

Microphysiological systems (MPS) hold promise for improving therapeutic drug approval rates by providing more physiological, human-based, in vitro assays for preclinical drug development activities compared to traditional in vitro and animal models. The full impact of MPS technologies will be realized only when robust approaches for in vitro-in vivo (MPS-to-human) translation are developed and utilized and explain how the burgeoning field of quantitative systems pharmacology (QSP) can fill that need.

15:00 Refreshment Break

15:30 Credibility/Validity of Complex in vitro Models: Crowdsourcing Strategies to Facilitate Acceptance and Use

Sofia Batista Leite, PhD, Scientific/Technical Project Officer, Chemical Safety and Alternative Methods, ECVAM, European Commission – Joint Research Centre (EC-JRC)

Complex in vitro models aim to represent higher-level anatomical and physiological aspects of human biology. Combined with their fast developing technology, these models are very attractive to multiple research and regulatory areas. Further implementation could be achieved by establishing a standardized framework for their assessment. More than 500 people responded to an EURL-ECVAM survey sharing their opinion on if/how such framework should/could be established. The survey results will be presented.

16:00 A Human Heart-Liver Platform to Study Acute and Chronic Cardiotoxicity upon Hepatic Biotransformation

Anne Riu, PhD, Project Manager, Research and Innovation, L’Oréal

Regulation of cosmetic testing has spurred efforts to develop new methods for systemic toxicity, however, in vitro assays are often lacking xenobiotic metabolism. A heart-liver system was developed to study metabolism-dependent cardiotoxicity combining functional cardiac and metabolically competent hepatic modules maintained under flow for 14 days. The system was characterized with a set of reference compounds and then evaluated with cosmetic ingredients.

16:30 Gut-on-a-Chip Models for Evaluating Efficacy and Safety

Nikolche Gjorevski, PhD, Scientist, Mechanistic Safety, Pharmaceutical Sciences, Roche

17:00 Close of Symposium


18:0020:30 Recommended Dinner Short Course*

쇼트코스 3:장기 칩 시스템의 기점, 최적화, 응용

* Separate registration required.

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.

Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English



Catalog Download
Catalog




메일링 서비스